Cardiovascular Disease Risk Among Transgender People with HIV.
Madeline CetlinEvelynne S FuldaSarah M ChuOle-Petter R HamnvikTonia PoteatMarkella V ZanniMabel ToribioPublished in: Current HIV/AIDS reports (2021)
Among transgender women and men, prospective longitudinal studies have shown that gender-affirming hormonal therapy (GAHT) is associated with select deleterious cardiometabolic effects such as increases in visceral adipose tissue. Retrospective studies among transgender women and men suggest an increase in CVD risk, such as venous thromboembolism, cerebrovascular accidents, and myocardial infarction. Studies among transgender PWH adhering to GAHT and ART suggest heightened systemic immune activation/inflammation. Prospective longitudinal studies assessing factors associated with increased CVD events among transgender PWH are needed to guide the development of CVD prevention strategies in this at-risk population.
Keyphrases
- hiv testing
- men who have sex with men
- venous thromboembolism
- adipose tissue
- cardiovascular disease
- case control
- polycystic ovary syndrome
- insulin resistance
- cross sectional
- hiv infected
- hiv positive
- antiretroviral therapy
- oxidative stress
- type diabetes
- heart failure
- metabolic syndrome
- human immunodeficiency virus
- mental health
- stem cells
- middle aged
- hiv aids
- mesenchymal stem cells
- high fat diet
- coronary artery disease
- breast cancer risk
- south africa
- atrial fibrillation